Agios Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 65 to 84 Friday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest price moves.
Looking For Winning Stocks? Try This Simple Routine
Agios Pharmaceuticals is not currently showing a potential entry point. It did not have much a move after earnings were released, but something has moved the stock higher recently. See if the stock goes on to build a sound pattern that could offer a proper entry point rather than chasing an extended stock.
AGIO Stock Earnings
Agios Pharmaceuticals reported 0% earnings growth in the latest quarterly report. Sales increased 65%.
The company earns the No. 120 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences and Alkermes are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
